Beat Childhood Cancer Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2020
NCT04301843
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Beat Childhood Cancer

Active Ingredients

Drugs in Phase 2 Trials (1)

eflornithine (ornidyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroblastoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1